


Exome Sequencing Points to Differences in Genenetic Instability Level in MGUS Compared to MM

Aneta Mikulasova

Brian A. Walker, Christopher P. Wardell, Eileen M. Boyle, Marketa Wayhelova, Jan Smetana, Petr Kuglik, Roman Hajek, Gareth J. Morgan



20th EHA Congress, Vienna (13rd June 2015)

Babak Myeloma Group, Dept. of Path. Physiology
Faculty of Medicine, Masaryk University, CZ

Dept. of Experimental Biology,
Faculty of Science, Masaryk University, CZ

Division of Molecular Pathology
Institute of Cancer Research, London, UK



Babak Myeloma Group
Dept. of Pathological Physiology
Faculty of Medicine, Masaryk University




Disclosure

Aneta Mikulasova


no relevant conflicts of interest to disclose

Monoclonal Gammopathies (MG)



Feature	MGUS	SMM	MM
BMPC (%)	<10	≥ 10	≥ 10
Serum M-protein (g/dL)	<3	≥ 3	≥ 3
Clinical manifestation	Absent	Absent	Present


Evolution of Methods in MG



Clonal expansion of genetic abnormal PCs during malignant transformation of MGUS to MM

Lopéz-Corral L. *et al.* 2011. Clin. Cancer Res. 17(7): 1692-1700.

Evolution of Methods in MG



López-Corral L. *et al.* 2012. *Leukemia* 26(12): 2521-2529.


Evolution of Methods in MG

Cytogenetics

FISH

aCGH

NGS



**SNVs number increasing
from MGUS to MM**

Walker B. et al. 2014. Leukemia 28(2): 384-390.

Aim of Study

Analysis of **somatic gene mutations (SNVs)** by exome sequencing together with **copy-number alterations (CNAs)** by CGH+SNP arrays in MGUS patients to describe comprehensive genetic instability at both gene and chromosome level.

MM cohorts for comparison:

33 MM cohort analysed by aCGH

463 MM cohort analysed by NGS
(Walker *et al.* 2015)



Methods

Peripheral Blood

Bone Marrow

Abnormal PCs separation

CD138⁺CD19⁻CD56^{+/-}

FACSAria (BD Biosciences)

DNA isolation

DNA isolation, **whole genome amplification**

n=33

Exome Sequencing

SureSelect Human All Exom V5 (Agilent) capture enriched by *IGH*, *IGK*, *IGL* and *MYC* HiSeq 2000 (Illumina), 4 pooled samples per one lane, 76-bp paired ends reads

n=97

CGH+SNP arrays

SurePrint G3 CGH+SNP, 4x180K (Agilent) Microarray Scanner (Agilent)

Data Analysis

SNP array data analysis: Feature Extraction Software, Genomic Workbench (both Agilent)

Exom data viewer: Integrative Genomics Viewer (Broad Institute)

Exom data processing tools and algorithms: FastQC, BWA/Stampy, GATK, Picard (Broad Institute)

Exom data analysis: MuTect, Indelocator, SnpEff, MutSigCV (Broad Institute)

Basic statistics: Statistica (StatSoft), MedCalc (MedCalc Software)

Differences in Whole Genome Profiling of CNAs

Genome-wide profiles of CNAs

MGUS (n=97)

GAINS

LOSSES


MM (n=33)

68% (66/97)

100% (33/33)

$P=3.20 \times 10^{-5}$

Number of CNAs per patient




MGUS
2 (0-22)

MM
14 (4-38)


$P=1.53 \times 10^{-11}$

Numerical and structural CNAs distribution




Numerical CNAs

Non-hyperdiploid MGUS is usually diploid, while MM hypo/pseudodiploid.




61% (59/97)
39% (38/97)



42% (14/33)
58% (19/33)


P=0.071

=> PRIMARY EVENT



Distribution of whole chromosome gains is similar to MM.

Structural CNAs



Frequency of structural CNAs is significantly lower in MGUS compared to MM.

Potential risk chromosome areas:


12p loss

17p loss

10p loss


20q loss

6p loss



chr12

ETV6
CDKN1B
BCL2L14
GPRC5A



chr17


TP53
HIC1
MYBBP1A

Chromosome Translocations

33 MGUS compared to 463 MM analysed by NGS (Walker *et al.* 2015)

***IGH* gene (14q32.33) translocations are present in similar frequency in MGUS compared to MM.**

=> PRIMARY EVENT




No MGUS case with ***MYC*** (8q24.21), ***IGK*** (2p12) and ***IGL*** (22q11.2) gene translocations

Somatic Gene Mutations

33 MGUS compared to 463 MM analysed by NGS (Walker *et al.* 2015)

	MGUS	MM
All SNVs	100% (33/33)	100% (463/463)
NS-SNVs	97.0% (32/33)	99.8% (462/463)

△ MGUS
○ MM



Somatic mutations are present in all MGUS patients, but in significantly lower level compared to MM.

Somatic Gene Mutations

33 MGUS compared to 463 MM analysed by NGS (Walker et al. 2015)

6 myeloma-significantly mutated genes:



MGUS	Gene	Mutation
1	EGR1 LTB	c.85A>C (p.M29L) c.167C>T (p.T56M)
2	KRAS NRAS	c.182A>T (p.Q61) c.37G>C (p.G13R)
3	HIST1H1E HIST1H1E PRKD2	c.169G>C (p.V57L) c.266G>C (p.S89T) c.1697A>G (p.Y566C)
4	KRAS	c.436G>A (p.A146T)
5	HIST1H1E DIS3	c.193G>C (p.A65P) c.1462G>A (p.D488N)

KRAS
NRAS
HIST1H1E
DIS3
EGR1
LTB

Genes with a negative impact on MM survival:

TP53, ATM, ATR, ZFHX4 genes involved in DNA repair pathway – **none**
CCND1 gene - **MGUS case** with two mutations (p.K50T, p.E51D)

SNVs in Context to CHAs



Genetic instability is formed at chromosome and gene level.


Positive correlation of increasing CNAs and SNVs.

Genetic Instability in Context to Clinical Data


Risk-stratification model by Rajkumar *et al.* 2005:

serum MIG ≥ 15 g/l, non-IgG subtype, abnormal FLC ratio

CHAs




NS-SNVs



Median number of CHAs per patient is increasing across the risk groups.

Summary

- Exome sequencing and SNP arrays genome-wide analysis showed **genetic instability formation precedes clinical manifestation** and at both gene and chromosome level.
- Gene level changes precede chromosome level changes.
- We confirmed *IGH* translocation and hyperdiploidy are primary genetic events.
- Overall **genetic instability is very heterogenous** in both MGUS and MM, but more complex in MM.
- **Frequency and level of CNAs and SNVs are significantly lower in MGUS.**



Babak Myeloma Group,
Dep. of Pathological
Physiology,
Faculty of Medicine, MU

Ševčíková Sabina

Bešše Lenka
 Kubaczková Veronika
 Sedlaříková Lenka
 Gromesová Barbora
 Štánková Monika
 Kuťálková Kateřina
 Bollová Božena

Dep. of Clinical Hematology,
Faculty Hospital Brno
Penka Miroslav



Almáši Martina
 Bezděková Renata
 Hanáková Božena
 Říhová Lucie
 Sábliková Barbora
 Suská Renata
 Štouračová Marcela
 Všianská Pavla

The Institute of Cancer
Research
London, UK

Morgan Gareth J.
 Wardell Christopher P.
 Walker Brian A.
 Kaiser Martin
 Boyle Eileen M.

Dep. of Clinical Hematology
Faculty Hospital Ostrava

Hájek Roman 

Jelínek Tomáš
 Kryukov Fedor
 Kryukova Elena
 Kuřová Zuzana

Laboratory of molecu-
cytogenetics



Dep. of Experimental Biology,
Faculty of Science, MU

Kuglík Petr

Mikulášová Aneta
 Smetana Jan
 Wayhelová Markéta
 Janyšková Helena

Dep. of Internal Medicine -
Hematology

Faculty Hospital Brno

Adam Zdeněk
 Krejčí Marta
 Pour Luděk



Institute of biostatistics
and analysis

Jarkovský Jiří
 Brožová Lucie
 Budinská Eva
 Ihnatová Ivana

